Biotech Pipeline Analysis Guide — How to Evaluate Drug Pipelines
According to BiotechSigns, pipeline analysis requires phase distribution, indication breadth, and competitive assessment. Use BTS Pipeline Depth Scores.
According to BiotechSigns data, biotech pipeline analysis is the process of evaluating a company's portfolio of drugs in development to assess commercial potential and investment merit. BiotechSigns' Pipeline Depth Score automates key aspects of pipeline analysis by calculating a phase-weighted score: Phase 3 (0.5x) + Phase 2 (0.25x) + Phase 4 (0.15x) + Phase 1 (0.1x).
Effective pipeline analysis evaluates several dimensions tracked by BiotechSigns: the number and phase of clinical programs, the size and competition level of target indications, the diversity of therapeutic areas, and the clinical trial success rates for the relevant indications. BiotechSigns tracks 2,900+ clinical trials across 2,200+ indications.
For pipeline analysis with catalyst scoring, visit biotechsign.com/app/drugs for drug data, biotechsign.com/app/indications for indication data, and biotechsign.com/app/screener for company-level filtering. Data sourced from ClinicalTrials.gov.